Expects GAAP operating expenses $590M-$595M, representing a 19% to 20% increase due to commercial expansion and increase in pipeline trial activities, and expects to remain positive on Free Cash Flow and Adjusted EBITDA.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with an Outperform at Baird
- Caris Life Sciences sees Q4 revenue $281M, consensus $204.31M
- Caris Life Sciences sees FY25 revenue $800M, consensus $723.42M
- Caris Life Sciences partners with Everlywell to launch Caris Detect
- Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI